Q32 Bio enters $14 million at-the-market equity distribution agreement; Cantor Fitzgerald commission set at 3.0%
Homology Medicines, Inc. QTTB | 5.05 | +2.64% |
- Q32 Bio entered a Controlled Equity OfferingSM sales agreement with Cantor Fitzgerald to sell common stock through an at-the-market program.
- The prospectus supplement covers up to USD 14.2 million of shares that may be offered and sold under the program.
- Cantor Fitzgerald will receive a 3% cash commission on gross proceeds from shares sold.
- Sales may be made on Nasdaq or other trading markets for the shares, subject to parameters set by Q32 Bio.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-129431), on March 27, 2026, and is solely responsible for the information contained therein.
